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In vitro assays are economical and easy to perform but to establish relevance of their results to real clinical outcome in animals
or human, pharmacokinetics is prerequisite. Despite various in vitro pharmacological activities of extracts of Piper sarmentosum,
there is no report of pharmacokinetics. Therefore, the present study aimed to evaluate ethanol extract of fruit of the plant in dose of
500mg kg−1 orally for pharmacokinetics. Sprague-Dawley rats were randomly divided into groups 1, 2, and 3 (each n = 6) to study
absorption, distribution and excretion, respectively. High performance liquid chromatography (HPLC) with ultraviolet detection
was applied to quantify pellitorine, sarmentine and sarmentosine in plasma, tissues, feces and urine to calculate pharmacokinetic
parameters. Pellitorine exhibited maximum plasma concentration (Cmax) 34.77 ngmL−1± 1.040, time to achieve Cmax (Tmax) 8 h,
mean resident time (MRT) 26.00 ± 0.149h and half life (t1/2) 18.64 ± 1.65 h. Sarmentine showed Cmax 191.50 ± 12.69ng mL−1,
Tmax 6 h, MRT 11.12 ± 0.44 h and t1/2 10.30 ± 1.98 h. Sarmentosine exhibited zero oral bioavailability because it was neither
detected in plasma nor in tissues, and in urine. Pellitorine was found to be distributed in intestinal wall, liver, lungs, kidney, and
heart, whereas sarmentine was found only in intestinal wall and heart. The cumulative excretion of pellitorine, sarmentine and
sarmentosine in feces in 72 h was 0.0773, 0.976, and 0.438 µg, respectively. This study shows that pellitorine and sarmentine have
good oral bioavailability while sarmentosine is not absorbed from the gastrointestinal tract.
1. Introduction
Pharmacokinetics, the action of body on the drug, includes
absorption, distribution, metabolism and excretion. Thera-
peutic outcome depends on the rate and extent at which drug
reaches at the site of action, bioavailability. Pharmacokinetic
parameters help to establish bioequivalence in-between
formulations and to understand toxicology, drug exposure.
Pharmacokinetic studies of herbs may also assist physicians
in prescribing drugs safely and eﬀectively to those patients
who are consuming herbal products, because herbs may syn-
ergies or antagonise the drugs, herb-drug interactions [1, 2].
Since long, natural product scientists have been studying
pharmacodynamics, the action of herbs on the body but less
attention has been paid to study the eﬀect of body on herbs.
This has been witnessed by a study indicating only few phar-
macokinetic reports on herbal preparations [3]. Unlike phar-
maceuticals, pharmacokinetics of herbal products, mixture
of known and unknown components, is always challenging
due to their complexity and unavailability or inadequacy of
standards and methods. Moreover, lack of pharmacokinetic
studies is a biggest hindrance in the modernization of
herbal products because there is no way to establish bioe-
quivalence between products prepared by modified method
and the original method [4]. Diﬀerent types of marker
compounds, characteristics to a particular plant, can be used
to study the pharmacokinetics of these preparations. Using
marker compounds, few herbal products such as Ginkgo
biloba, Allium sativum, Ephedra sinica, Artemesia annua,
and so forth, have been investigated for pharmacokinetics
[5–8].
Pharmacokinetic studies are of prime importance prior
to clinical trials of herbal products to make these remedies
evidence-based drugs. The importance of pharmacokinetics
of herbal products has also been emphasized in the literature
[9]. Keeping this in view, a commercially important medici-
nal plant, Piper sarmentosum, has been selected in this study
to evaluate its extracts for pharmacokinetics.
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Piper sarmentosum is a tropical plant, used traditionally
in South-East Asian region to cure various ailments [10–13].
The plant has also been investigated extensively for a number
of pharmacological activities such as anti-amoebic [14],
antibacterial [15], anti-TB [16], anti-neoplastic [12], neu-
romuscular blocking [17], hypoglycemic [18], anti-malarial
[19], antioxidant [16, 20, 21] and antiangiogenic [22].
Based on these activities, from extracts of the plant various
products are being manufactured and are being sold as
nutraceuticals nowadays. Despite these developments, there
is no report about pharmacokinetic studies on these extracts.
These studies are prerequisite to understand whether the
extracts are absorbed from gastrointestinal tract or not.
The plant is reported to have a number of biologically
active amides [23–25] and amongst these, we have selected
pellitorine, sarmentine and sarmentosine to develop and
validate a high performance liquid chromatography (HPLC)
method for their simultaneous quantification, and to apply
the method to study pharmacokinetics of ethanol extracts of
fruit of the plant.
Two approaches, non-compartment and compartment
model, are commonly used to evaluate the pharmacokinetic
profile of a compound. Compartment models such as one
compartment model, two- and three-compartment model
are associated with more assumptions as compared with
non-compartment model. Therefore, we have used non-
compartment model in this study to evaluate pharmacoki-
netic profile of the markers in the extract using Trapezoidal
rule [26].
2. Methods
2.1. Animals and Grouping. Male Sprague-Dawley rats
weighing 313 ± 17 g, taken from the Animal House of
the Universiti Sains Malaysia, Pulau Penang, were housed
in standard cages in animal transit room of the School
of Pharmaceutical Sciences, for 7 days to acclimatise.
Standard pellet diet (Gold Coin, Penang, Malaysia) was
given and tap water was supplied ad libitum. Animals
were divided into three groups (n = 6). Group 1 was
used to study oral absorption while Group 2 was used to
evaluate tissue distribution. Group 3 was further divided
into two sub-groups (n = 3) namely subgroup E and
subgroup C. The animals of subgroup-E were used to
study excretion of markers in feces and urine while
subgroup C served as control. The study protocol was
approved by the Animal Ethical Committee of the Uni-
versiti Sains Malaysia; vide reference #USM/PPSF/50 (009)
Jld.
2.2. Preparation Extract and Dose. The fruit of the plant
collected from the Botanical Garden of the School of
Pharmaceutical Sciences, Universiti Sains Malaysia, was
authenticated by Prof. Dr Zhari Ismail, Herbal Secretariat,
School of Pharmaceutical Sciences, Universiti SainsMalaysia,
where a voucher specimen was deposited vide reference No.
0071/06. The fruit was cleaned, sliced into small pieces,
dried at 40◦C and pulverized. The pulverized fruit material
(50 g) was extracted twice with 300mL ethanol by reflux
for 1 h. The extract was filtered and dried in vacuo at
40◦C. The markers were quantified in the extract by HPLC
before preparing the dose, which was prepared by suspending
the extract in a mixture of water and polyethylene glycol
(PEG) 400 in a ratio of 1 : 1 v/v to get final concentration
100mgmL−1.
2.3. Collection of Blood Samples for Absorption Studies. A
dose of 500mg kg−1 was administered orally to six overnight
fasting rats of Group 1. Blood samples (0.5mL) were
collected from tail vein [27, 28] in EDTA coated tubes
(Becton Dickinson and Company) at 0 min (pre dose), 0.5,
1, 2, 4, 6, 8, 12, and 24 h. The tubes containing blood were
centrifuged at 2500 rpm at 10◦C for 10min to get plasma,
which was then stored at −80◦C until analyzed.
2.4. Sampling for Tissue Distribution Studies. A dose of
the extract (500mg kg−1) was administered orally to six
overnight fasting rats of group 2 and food was withheld for
further 1 h. Blood samples (0.5mL) were collected from the
tail vein at 0 min (pre-dosing) and 6 h, then the animals were
sacrificed to get tissues such as intestine, liver, lungs, kidney
and heart. Blood samples were centrifuged at 2500 rpm at
10◦C for 10min to get plasma samples, which were then
stored at −80◦C until analyzed. Frozen tissues were used
to prepare 5% homogenate in 0.15M potassium chloride.
These homogenates were centrifuged at 2500 rpm at 10◦C
for 10min and the supernatant was stored at −80◦C until
analyzed.
2.5. Collection of Urine and Excreta. A dose of the extract
(500mg kg−1) was administered orally to overnight fasting
rats of subgroup-E and food was withheld for further 1 h.
The animals of subgroup-C received the equivalent amount
of vehicle which was used to prepare the dose, and served
as control. The animals were housed in metabolic cages to
collect urine and feces. The samples were collected at 0min
(pre-dosing) and subsequently at 5, 10, 24, 48, and 72 h.
The samples were then extracted according to the protocol
mentioned below and the extracted samples were stored at
−80◦C until analyzed.
2.6. Extraction of the Markers from
Plasma, Tissues, Urine and Feces
2.6.1. Plasma. Rat plasma (500 µL) taken in centrifuge tube
was mixed with acetonitrile (100 µL) by vortex for 5 s. Then
1mL ethyl acetate was added and mixed by vortex for 5 s,
afterwards the tube was centrifuged at 3000 rpm for 5min at
10◦C. The supernatant was collected and dried with stream
of nitrogen, and the residue was reconstituted with 500 µL
mobile phase.
2.6.2. Urine. One-milliliter urine was taken in centrifuge
tube containing 1mL ethyl acetate. The tube was vortex for
5 s, centrifuged at 3000 rpm at 10◦C for 5min and the non-
aqueous layer was collected, dried with stream of nitrogen,
and the residue was reconstituted with 500 µL mobile
phase.
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2.6.3. Tissues. Three milliliter of 5% liver homogenate pre-
pared in 0.15M potassium chloride was taken in a centrifuge
tube containing 200 µL acetonitrile. The tube was vortex for
5 s and after adding 2mL ethyl acetate, tube was vortex again
for 5 s. Then the tube was centrifuged at 3000 rpm at 10◦C for
5min, supernatant was collected and dried, and the residue
was reconstituted with 500 µL mobile phase.
2.7. Fecal Matter. Wet fecal matter (500mg) was dissolved in
2mL ethyl acetate, vortex for 5 s and centrifuged at 3000 rpm
for 5min. The supernatant was collected and dried, and the
residue was reconstituted with 500 µL mobile phase.
All the samples were filtered through 0.45 µm polyte-
trafluoroethylene (PTFE) syringe filter (Whatman, Maid-
stone, England) and kept in HPLC vials.
2.8. Chromatography and Quantification of the Markers.
Standards (pellitorine, sarmentine and sarmentosine) pre-
viously isolated from fruit of P. sarmentosum were used to
prepare mix standard stock solution as: 300 µg pellitorine,
300 µg sarmentosine and 200 µg of sarmentine were dissolved
in 1mL methanol. The stock solution was further diluted
with mobile phase to get a series of mix working standard
solutions containing pellitorine and sarmentosine 0.03–
3.00 µg mL−1 and sarmentine 0.02–2.00 µg mL−1.
All the samples were analyzed using HPLC system (1100
series, Agilent Technologies, Waldronn, Germany) equipped
with degasser (G1379 A), quaternary pump (G1311 A), auto
sampler (G1313 A), column oven (G1316 A) and ultraviolet
(UV) detector (G 1314 A).
The samples (15 µL) were eluted by an isocratic mobile
phase comprising of methanol : water : acetonitrile (80 : 15 : 5
v/v) at flow rate of 1mLmin−1 through column (Hiber
Rt 250-4, LiChrosorb RP 18, 10 µm, Agilent Technologies),
which was maintained at 25◦C. The elution time was 15 min
and the detection was carried out at 260 nm by operating the
detector in a sensitivity range of 0.005 AUFS with output of
15mV. The data acquisition was performed by ChemStation
version A. 08.03 and the markers were quantified by external
standard method.
2.9. Determination of Pharmacokinetic Parameters. Analyti-
cal data of each rat was used to plot plasma concentration
versus time. Total area under the plasma concentration ver-
sus time curve (AUC0−∞) was calculated using Trapezoidal
rule [26] which is given as follows:
AUC0−∞ =
∑
(AUC0−1 + AUC1−last + AUClast−∞), (1)
where AUClast−∞ = Clast/Kel.
A plot of product of concentration and time (CT) versus
time was used to calculate area under first moment curve
(AUMC). Mean resident time (MRT) was determined by
dividing AUMC0−∞ with AUC0−∞ The maximum plasma
concentration Cmax (ngmL−1) and the time to achieve
Cmax, Tmax (h), were obtained directly from the data. The
elimination rate constant Kel (h−1) was calculated by linear
regression from the terminal phase of the plot of plasma
concentration versus time using following equation:
Kel = lnC1 − lnC2T2 − T1 . (2)
The half-life t1/2 (h) was calculated by dividing 0.693 with
Kel. The clearance (Cl) and the volume of distribution (VD)
were calculated from the equations given as follows:
Cl = Actual dose administered
AUC0−∞
, (3)
VD = Clearence (Cl)
Elimination constant(Kel)
. (4)
2.10. Statistical Analysis. Each sample has been analyzed in
triplicate and the results are presented as mean ± standard
deviation (SD). The values of pharmacokinetic parameters
for absorption and distribution are the average of six rats ±
SD while the excretion values are the average of three rats ±
SD.
3. Results
3.1. Validation of HPLC Method of Analysis. The results
shown in (Table 1) indicate the calibration data, limit of
detection (LOD) and limit of quantification (LOQ) of pelli-
torine, sarmentine and sarmentosine. The method has been
found linear over the whole range of samples investigated
with correlation coeﬃcients (R2) ranging from 0.9997 to
1.0000 with SD <5%. It is obvious in the table that LOD
values of pellitorine, sarmentine and sarmentosine are 3.00,
3.00, and 20.00 ngmL−1, respectively, while 10.00, 10.00 and
80.00 ngmL−1, respectively, have been taken as LOQ at signal
to noise ratio 10 : 1. Extraction recovery values of pellitorine,
sarmentine and sarmentosine are found to be 95.52–97.50,
96.23–98.43, and 96.47–100%, respectively, with relative SD
<5%. Intra- and inter-day analysis accuracy values of the
markers are 97.97–100.19% with relative SD <5%. These
results have indicated that the method is reliable, repeatable
and reproducible because the recovery of the markers is not
compromised in intra- and inter-day analysis.
3.2. Content of the Markers in the Extract, Plasma, Tissues,
Urine, and Feces. Before the preparation of dose, the content
of markers, pellitroine, sarmentine and sarmentosine, were
determined in the extract by HPLC and found to be
52.10, 13.10, and 0.21mg g−1, respectively. This standardized
extract was administered orally in a dose of 500mg kg−1
to rats and the samples obtained at specified intervals were
analyzed in triplicate by HPLC to quantify the markers in
plasma, tissues, urine, and feces. These values were then
used to calculate diﬀerent pharmacokinetic parameters. The
chromatograms of mix standard solution, the extract, blank
plasma, markers in plasma and tissues, whereas pharmacoki-
netic data of pellitorine and sarmentine.
3.3. Pharmacokinetic Parameters of the Markers. The results
of pharmacokinetic parameters of pellitorine and sarmentine
4 Evidence-Based Complementary and Alternative Medicine
Table 1: Results of calibration, LOD, and LOQ of pellitorine, sarmentine and sarmentosine by HPLC with UV detection at 260 nm.
Standards Linear regression equation R2 Linear range (ng mL−1) LOD (ng mL−1) LOQ (ng mL−1)
Pellitorine Y = 0.2156X−0.0333 1.0000 10–500 3.00 10.00
Sarmentine Y = 0.0985X−1.2335 0.9979 10–1500 3.00 10.00
Sarmentosine Y = 0.0424X−1.4979 0.9999 80–12000 20.00 80.00
Table 2: Pharmacokinetic parameters of pellitorine in rats (n = 6) following an oral dose (500mg kg−1) of ethanol extract of fruit of
P. sarmentosum.
Rat 1 2 3 4 5 6 Mean ± SD
AUC0−∞ (ng hmL−1) 1154.352 989.1177 1013.913 979.7302 978.4666 1107.007 1037.098± 75.10543
AUMC0−∞ 29 997.640 25 654.080 26 668.00 25 454.990 25 399.670 28 650.570 26 970.830 ± 1927.431
MRT (h) 25.987 25.937 26.302 25.982 25.959 25.881 26.008 ± 0.149
T1/2 (h) 21.397 17.617 17.290 19.045 17.087 19.436 18.645 ± 1.654
Cmax (ngmL−1) 33.880 33.420 36.310 34.710 34.870 35.460 34.775± 1.047
Tmax (h) 8.000 8.000 8.000 8.000 8.000 8.000 8.000 ± 0.000
Kel (h−1) 0.033 0.039 0.040 0.036 0.046 0.037 0.038 ± 0.005
Cl 0.065 0.085 0.0751 0.086 0.087 0.071 0.078 ± 0.008
VD 1.993 2.158 1.877 2.355 2.135 1.972 2.082 ± 0.156
are presented in Tables 2 and 3, respectively. These results
indicated that pellitorine exhibited Cmax 34.77 ± 1.04 ng
mL−1, Tmax 8 h, MRT 26.00 ± 0.149 h and t1/2 18.64 ± 1.65
h, whereas sarmentine showed Cmax 191.50± 12.69 ngmL−1,
Tmax 6 h, MRT 11.12 ± 0.44 h and t1/2 10.30 ± 1.98 h. The
plasma concentration versus time profiles of pellitorine and
sarmentine are presented in Figures 1 and 2, respectively. It is
evident from these results that sarmentine stays in the body
for lesser time as compared with pellitorine. Sarmentosine
exhibited zero oral bioavailability because it was neither
detected in plasma nor in tissues, feces and urine.
3.4. Tissue Distribution of the Marker Compounds. The tissue
distribution profiles of the markers in diﬀerent tissues are
presented in Figure 3. These results showed that pellitorine
and sarmentine had diﬀerent aﬃnities toward diﬀerent
tissues. Pellitorine was found in intestinal wall, liver, lungs,
kidney, and heart, whereas sarmentine was found in intesti-
nal wall and heart.
3.5. Excretion of the Markers in Urine and Feces. The
chromatograms of urine samples indicated that pellitorine
and sarmentine were not excreted in urine as unchanged.
It was expected that both the markers were metabolized
to polar compounds to be excreted in urine. The same
was noticed from chromatograms of urine samples, which
indicated the increase in polarity of the samples that were
collected after 5 h. Moreover, the polarity of urine samples
was observed to becoming normal after 72 h.
The eﬀect of the extract on urine output in 24 h presented
in Table 4 indicated that there was not any significant
diﬀerence in urine volume in both experimental group and
control group (P < .05).
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Figure 1: Pharmacokinetic profile of pellitorine after administering
oral dose of 500mg kg−1 of fruit ethanol extract of P. sarmentosum
(each point is mean of six rats ± SD).
0
25
50
75
100
125
150
175
200
225
0 2 4 6 8 10 12 14 16 18 20 22 24
Time (hrs)
(n
g/
m
L)
Figure 2: Pharmacokinetic profile of sarmentine after admin-
istering oral dose of 500mg kg−1 of fruit ethanol extract of P.
sarmentosum (each point is mean of six rats ± SD).
The results of excretion of the markers in feces presented
in (Table 4) indicated that cumulative excretion of pellitorine
0.0773 µg in 0–72 h, which was 0.0007% of the oral dose.
The oral bioavailability of pellitorine is considered good
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Table 3: Pharmacokinetic parameter of sarmentine in rats following an oral dose (500mg kg−1) of ethanol extract of fruit of P. sarmentosum.
Rat 1 2 3 4 5 6 Mean ± SD
AUC0−∞ (ng hmL−1) 5078.443 5304.598 4674.769 4684.233 4749.764 4900.847 4898.776± 251.1527
AUMC0−∞ 55 489.980 60 942.670 55 318.870 51 450.740 51 587.150 52 239.930 54 504.890 ± 3634.530
MRT (h) 10.927 11.489 11.834 10.984 10.861 10.659 11.126 ± 0.443
T1/2 (h) 10.380 11.873 13.183 7.668 9.714 9.023 10.307 ± 1.985
Cmax (ngmL−1) 196.547 194.318 166.476 194.929 194.54 202.669 191.580± 12.691
Tmax (h) 6.000 6.000 6.000 6.000 6.000 6.000 6.000 ± 0.000
Kel (h−1) 0.089 0.078 0.070 0.121 0.095 0.103 0.093 ± 0.018
Cl 0.004 0.004 0.004 0.005 0.005 0.004 0.004 ± 0.000
VD 0.042 0.052 0.059 0.038 0.048 0.039 0.047 ± 0.008
Table 4: Cumulative excretion of pellitorine, sarmentine and sarmentosine in feces after oral dose of 500mg kg−1 of ethanol extract of fruit
of P. sarmentosum, and outcome of the extract on urine volume in experimental and control groups.
Excretion parameters Rat 1 Rat 2 Rat 3 Mean SD
Excretion of pellitorine
Cumulative amount in µg (0–72 h) 0.091 0.0564 0.0845 0.0773 0.0183
Percent of dose 0.001 0.001 0.001 0.001 0.000
Peak time (h) 48.000 48.000 48.000 48.000 0.000
Maximum excretion rate (µg h−1) 0.002 0.002 0.002 0.002 0.000
Excretion of sarmentine
Cumulative amount in µg (0–72 h) 1.2176 0.866 0.844 0.976 0.2093
Percent of dose 0.0041 0.0036 0.0035 0.0037 0.0003
Peak time (h) 24.000 24.000 24.000 24.000 0.000
Maximum excretion rate (µg h−1) 0.026 0.028 0.025 0.026 0.002
Excretion of sarmentosine
Cumulative amount in µg (0–72 h) 5.206 3.046 4.882 4.377 1.165
Percent of dose 1.117 0.653 1.047 0.939 0.249
Peak time (h) 24.000 24.000 24.000 24.000 0.000
Maximum excretion rate (µg h−1) 0.155 0.078 0.148 0.127 0.043
Urine volume in experimental group
Cumulative urinary volume in mL (0–24 h) 14.520 18.350 16.750 16.540 1.924
Maximum urine flow rate (mL h−1) 0.605 0.765 0.697 0.689 0.081
Control 1 Control 2 Control 3 Mean SD
Urine volume in control group
Cumulative urinary volume in mL (0–24 h) 15.670 17.340 14.430 15.813 1.461
Maximum urine flow rate (mL h−1) 0.653 0.723 0.602 0.659 0.061
Each value represents the mean of three rats ± SD.
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Figure 3: Concentration of pellitorine and sarmentine in diﬀerent
tissues of the rats (n = 3) at 6 h after administering oral dose (500mg
kg−1) of ethanol extract of fruit of P. sarmentosum.
because fewer amounts are excreted in feces. The cumulative
excretion of sarmentine was 0.976 µg in 0–72 h, which was
0.0037% of the oral dose. This marker also exhibited good
bioavailability but relatively lesser than pellitorine. The
cumulative excretion of sarmentosine was 0.4377 µg in 0–
72 h, which was 0.94% of the dose. This marker exhibited
zero oral bioavailability because it was excreted in feces as
unchanged. The comparison of cumulative excretion profile
of the markers in feces in 72 h is presented in Figure 4,
which indicated that maximum excretion occurred 48 h after
dosing.
4. Discussion
Keeping in view the versatile biological activities of extracts
of the plant, pharmacokinetic studies based on three
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Figure 4: Excretion profiles of pellitorine, sarmentine and sarmen-
tosine in feces after oral dose (500mg kg−1) of ethanol extract of
fruit of P. sarmentosum in rats.
markers, pellitorine, sarmentine and sramentosine, were
carried out in rats to delineate their absorption, distribution,
metabolism and excretion after administering the extract
orally. The oral route has certain merits and demerits, and
oral drug absorption is aﬀected by a number of factors; in
gastric lumen drug may be metabolized by enzymes and
microbial flora, inactivated by gastric contents and excreted
in feces. The fraction of the drug which is absorbed may
be metabolized in intestinal wall and in liver. Hence, the
amount of drug which reaches in systemic circulation is
lesser as compared with the administered dose. The action
of the drug depends on the rate and extent at which drug
reaches at the site(s) of action. Therefore, oral bioavailability
data of the extract may be beneficial for its safe and eﬀective
use. Pharmacokinetic parameters help to understand the
action of the body on the drug, which have numerous useful
applications both in toxicology and biopharmaceutics. In
present study, we have selected the oral route because the
plant and its products are taken orally. The areas under
curves of plasma concentration of pellitorine and sarmentine
versus time have shown that drug exposure is long, which
signifies the need of both the control of dose quantity and
dosing interval.
On the basis of the results of this study, the proposed
model for the pharmacokinetics of pellitorine, sarmentine
and sarmentosine is given in (Figure 5). The drugs absorbed
from gastrointestinal tract lead to liver, where these are
biotransformed and delivered into blood stream to reach
other organs. The appearance of pellitorine and sarmentine
in various tissues indicates that these markers are either not
metabolized or less metabolized in the liver. The absorbed
drug is excreted through various routes but kidneys are the
major organs involved in the excretion of most of drugs. In
this study, pellitorine and sarmentine were not detected in
urine, which indicated that either the markers were below
the detection limit or in the form of metabolites. Based
on chromatographic profiles, it was observed that both the
markers were converted into polar metabolites to be excreted
via urine. The polarity of the urine was observed to be
increasing after 5 h of the dose administration. The polarity
was found to be normal in samples that were collected after
Liver
1, 2
Oral dose
1, 2, 3
Gastrointestinal tract
1, 2, 3
Faeces 1, 2, 3
Ke
Ka
Bile
Blood
1, 2
Tissues
1, 2Urine
metabolites of 1, 2
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VD
Figure 5: Pharmacokinetic model of pellitorine, sarmentine and
sarmentosine after administering ethanol extract of fruit of P.
sarmentosum in rats, Ka (absorption rate constant); Ke (constant
elimination); VD (volume of distribution); 1 (pellitorine); 2
(sarmentine); 3 (sarmentosine).
72 h. It was found that these markers were excreted in urine
in the form of metabolites.
From the blood, drug distributes itself into various
tissues based on physicochemical properties of the drug itself,
eﬀective tissue perfusion and behavior of cell membranes
of the tissues. Selective tissue distribution of a drug is of
a great value in targeting specific tissues and organs. The
two absorbed markers have shown diﬀerent aﬃnities toward
diﬀerent tissues.
It is observed from the plasma concentration versus time
profiles of the absorbed markers that pellitorine declines
from 1 to 4 h followed by rise with maximum at 8 h while
sarmentine declines from 30min to 1 h followed by rise
with maximum concentration at 6 h. The fluctuation in
the plasma level time curve may be ascribed to a couple
of pharmacokinetic phenomena such as hepatic-cycling,
absorption from multiple-window and tissue distribution.
The presence of outlier(s) may also be expected however, a
consistent profile in all six animals excludes the probability
of outlier(s) in the plasma level time curve for these markers.
The fluctuation in plasma concentration versus time profile
is found to be due to tissue distribution, which is apparent
from tissue distribution profiles.
Sarmentosine is neither detected in plasma nor in tissues
therefore, may it be assumed that either this marker is
destroyed in gastrointestinal tract or excreted in the feces. It
becomes evident from the analysis of feces that this marker is
excreted unchanged without any absorption, and if absorbs,
may be lesser in amount which is below the limit of detection
of this method. This study suggests that this marker should
be administered using other routes of administration or need
to be modified to enhance its oral absorption.
It is evident from the study that the two markers of
the extract, pellitorine and sarmentine, have good oral
bioavailability and diﬀerent tissue aﬃnities, and are excreted
in urine as metabolites. The other marker, sarmentosine, is
Evidence-Based Complementary and Alternative Medicine 7
excreted unchanged in feces and is not absorbed from the
intestine.
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